Business Wire
23 Jun 2026, 07:30 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
CroíValve secured $20 million in Series B expansion financing and $7 million in grant financing from the EIC and DTIF. — Increased capitalization reduces liquidity risk and provides the necessary runway to advance the development of their tricuspid regurgitation device.
+0.40Total Series B funding has reached $36 million, increasing to $43 million when including grant financing. — A higher aggregate funding total signals strong investor confidence in the company's technology and clinical potential.
+0.30The financing round includes new institutional investors BGF and EIC, with participation from existing investor cur. — The addition of reputable new investors validates the company's value proposition to the broader market.
+0.20Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
21h ago
